Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insmed

Novavax

Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

3 Biotech Stocks to Monitor Right Now

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Moderna on Monday said its combination COVID-19 and flu shot elicits a stronger immune response against both viruses than licensed vaccines on the market, promising findings for the mRNA company as it works to diversify into areas like influenza and cancer amid diminishing demand for coronavirus shots.

Moderna's COVID-Flu Vaccine Shows Stronger Immune Response Than Individual Shots, Late-Stage Trial Finds

Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.

Moderna COVID/flu combo vaccine superior to separate shots in trial

Moderna Inc.'s MRNA, -2.38% experimental combination COVID and flu vaccine triggered better immune responses than stand-alone shots currently on the market, according to clinical trial data the company released Monday.

Moderna's combo COVID and flu vaccine works better than stand-alone shots on the market, study finds

Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. Moderna stock has risen this year.

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK

Moderna said its combination vaccine targeting Covid and the flu was more effective than existing standalone shots for those viruses in a late-stage trial.  The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rivals Pfizer and Novavax.

Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial. "Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna is at an inflection point with the recent FDA approval of its RSV vaccine. The company could have more new products on the way with its promising late-stage pipeline.

Why Moderna Stock Is a No-Brainer Buy Right Now

Moderna finally earned approval for a non-coronavirus vaccine. The company's cancer vaccine candidate looks very promising.

3 Reasons to Buy Moderna Stock

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1. "For four years, Moderna has consistently delivered vaccines that offer protection against COVID-19, and work is well underway to provide a vaccine targeting JN.1," said Stéphane Bancel, CEO of Moderna.

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

The stock price of Moderna has seen a sharp 27% rise in a month, while its peer – BioNTech – has seen its stock rise 10% over this period. Moderna has a couple of factors to back its strong run.

Should You Pick Moderna Stock At $150 After 25% Gains In A Month?

Moderna stock is on the rise amid a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?

Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?

Moderna, Inc. (NASDAQ:MRNA ) Jefferies 2024 Global Healthcare Conference June 6, 2024 10:00 AM ET Company Participants Jamey Mock - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee [Starts Abruptly] of Moderna, Jamey Mock, up here with us. Jamey, it's great to be here.

Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript)

Broadcom

Hewlett Packard

Lam Research

Micron Technology

The S&P 500 touches a record high for the 25th time this year, powered by technology stocks. We have highlighted five technology stocks, HPE, MRNA, AVGO, MU and LRCX, leading the way higher in the latest trading session.

5 Stocks Propelling S&P 500 to 25th Record High

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases CAMBRIDGE, MA / ACCESSWIRE / June 6, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency.

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Pfizer

WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus called JN.1.

FDA advisers urge targeting JN.1 strain in fall's COVID vaccines

AbbVie

Novo Nordisk

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

Moderna, Inc. (NASDAQ:MRNA ) Moderna Oncology Investor Event June 3, 2024 7:15 PM ET Company Participants Stephen Hoge - President Kyle Holen - Head of Development, Therapeutics and Oncology Michelle Brown - Vice President, INT Oncology Rose Loughlin - VP, R&D Strategy Lavina Talukdar - SVP & Head of IR Conference Call Participants Luca Issi - RBC Capital Markets Gena Wang - Barclays Dina Elmonshed - Jefferies Terence Flynn - Morgan Stanley Jess Fye - JPMorgan Myles Minter - William Blair Mani Foroohar - Leerink Partners Stephen Hoge We're going to get started. Thank you, everybody, for taking some time out of ASCO and your time here to spend with us.

Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript)

Merck

Cancer vaccines are finally showing promise as Moderna and Merck touted promising data on an experimental skin cancer vaccine and the U.K. announced plans for a “landmark” scheme to test the technology across the country this week, after decades of research that could bring a new era of personalized medicine.

What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck

Data from a key cancer conference has underlined the potential of a vaccine for melanoma that has now moved into late-stage clinical trials here in the UK.  Last month, we heard of the first dosing of Moderna Inc (NASDAQ:MRNA, ETR:0QF)'s potential breakthrough jab for a phase III study that could offer hope for sufferers of skin cancer when used in combination with Merck's Keytruda, a checkpoint inhibitor therapy.

Moderna cancer vaccine's potential revealed in phase II data

The RSV vaccine is Moderna???s (MRNA) second FDA-approved product.

Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine

Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin cancer. Nearly 75% of patients who took the combination were alive without any signs or symptoms of their cancer returning at the 2½-year mark.

Moderna, Merck say vaccine improved survival in patients with deadly skin cancer

Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.

Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up

At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell carcinoma CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / June 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (RFS), the primary endpoint of the study, reducing the risk of recurrence or death by 49% (HR [95% CI], 0.510 [0.288-0.906]; two-sided nominal p-value 0.019) compared with KEYTRUDA alone.

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II

News for Moderna Stock (MRNA)